Achieve Life Sciences · Nasdaq: ACHV · cytisinicline

Achieve's first 8-K to discuss the letter came on Aug 11, 2026. It describes the manufacturing and labeling issues and says the FDA identified no clinical efficacy or safety deficiencies. It does not mention the postmarketing pregnancy and lactation studies, the renal-dosing comment or the requested safety update.

The company's only 8-K between the letter and Aug 11, 2026 does not mention the letter. [8-K · searched] The Aug 11 8-K says the letter relates to “outstanding current Good Manufacturing Practice (cGMP) observations from an inspection of the Company’s prior third-party manufacturing facility” [8-K · Aug 11] and to “final product labeling that was not completed by the FDA’s action date” [8-K · Aug 11]. The 10-Q filed the same day adds that the facility “received an Official Action Indicated, or OAI, classification and a warning letter” [10-Q · Aug 11]. Letter page 1 (decision; items 1–2): scanned image, not verified here. [not in record]

The 8-K says “The FDA identified no deficiencies related to the clinical efficacy or safety of cytisinicline.” [8-K · Aug 11] The letter asks the company to “include a safety update” [FDA · Jun 20 · p. 3] and says that “if this application is approved, you will be required to conduct postmarketing studies to assess signals of serious risks of adverse maternal, fetal, or infant outcomes due to exposure to cytisinicline during pregnancy” [FDA · Jun 20 · p. 4]. The 8-K does not mention the safety update [8-K · searched] or the pregnancy and lactation studies. [8-K · searched] Neither of the company's 2026 10-Qs mentions pregnancy or lactation; [10-Q · searched] they say generally that “the FDA may require us to conduct additional clinical testing or to perform post-marketing studies, as a condition to granting marketing approval” [10-Q · Aug 11].

Among comments the letter says are “not approvability issues” [FDA · Jun 20 · p. 4], the proposed dosing in ESRD “is not adequately supported by the available pharmacokinetic data” [FDA · Jun 20 · p. 4]. Neither the 8-K nor the 10-Q mentions renal dosing. [8-K and 10-Q · searched] On next steps, the 8-K says “The Company intends to resubmit its NDA naming Adare as its finished drug product manufacturer for commercial supply in the fourth quarter of 2026” [8-K · Aug 11].

In May 2026, before the letter, Achieve said its prior manufacturer's facility had received an Official Action Indicated classification and that it expected a Complete Response Letter. Since then it has said it intends to resubmit in the fourth quarter of 2026 naming Adare, and in August anticipated potential approval in the first half of 2027.

On May 12, 2026 the company said its “prior third-party manufacturer facility received an Official Action Indicated classification” [8-K · May 12], “with observations not specific to cytisinicline” [8-K · May 12], and that it “expects to receive a Complete Response Letter from the FDA on or before June 20, 2026” [8-K · May 12]. It said “The Company intends to resubmit its New Drug Application in the fourth quarter of 2026, naming Adare as its new and primary manufacturing partner for commercial supply” [8-K · May 12].

The letter says the company must “resubmit or take other actions available under 21 CFR 314.110” [FDA · Jun 20 · p. 5] within one year. Letter page 1 (decision; items 1–2): scanned image, not verified here. [not in record]

In August, the 10-Q says the prior manufacturer “underwent a non-Achieve related FDA cGMP inspection and the FDA made observations, two of which were related to solid oral dose manufacturing” [10-Q · Aug 11], and the 8-K says the company “anticipates potential FDA approval in the first half of 2027, with U.S. commercial launch to follow” [8-K · Aug 11].

Page 1 of the published letter, which holds the decision and its first two items, is a scanned image, so it is not quoted here. The company says the letter relates to cGMP observations at its prior third-party manufacturer and to labeling. The readable pages ask for labeling changes and a safety update, set out postmarketing studies required if approved, and add comments that are not approvability issues.

The first page of the published letter, which carries the decision and the first two numbered items, is a scanned image without a text layer, so it is not quoted here. [not in record] The company's 8-K says “The CRL relates to outstanding current Good Manufacturing Practice (cGMP) observations from an inspection of the Company’s prior third-party manufacturing facility, which received an Official Action Indicated classification, and to final product labeling that was not completed by the FDA’s action date” [8-K · Aug 11].

The readable pages continue: “Prior to resubmitting the labeling, use the SRPI checklist to correct any formatting errors” [FDA · Jun 20 · p. 2]; item (3) asks to “Add the following bolded statement or appropriate alternative to the carton and container labeling” [FDA · Jun 20 · p. 2]; and the letter asks the company to “include a safety update” [FDA · Jun 20 · p. 3] when it responds.

It says that “if this application is approved, you will be required to conduct postmarketing studies to assess signals of serious risks of adverse maternal, fetal, or infant outcomes due to exposure to cytisinicline during pregnancy” [FDA · Jun 20 · p. 4], and on lactation.

Under comments it calls “not approvability issues” [FDA · Jun 20 · p. 4], it says “Disease (ESRD) patients is not adequately supported by the available pharmacokinetic data” [FDA · Jun 20 · p. 4]. A resubmission “must fully address all the deficiencies listed in this letter” [FDA · Jun 20 · p. 5].

In its Aug 11, 2026 filings the company says it intends to resubmit the NDA in the fourth quarter of 2026. Its 10-Q says resolving the manufacturing deficiencies is a prerequisite, and the letter's postmarketing studies would apply if the drug is approved.

The 10-Q says “resolution of the manufacturing-related deficiencies is a prerequisite to any resubmission of our NDA and subsequent approval by the FDA” [10-Q · Aug 11], and that there is no guarantee the FDA will agree any remediation is adequate, “which may require a pre-approval inspection of the facility” [10-Q · Aug 11]. The company “intends to resubmit its NDA naming Adare as its finished drug product manufacturer for commercial supply in the fourth quarter of 2026” [8-K · Aug 11].

If the drug is approved, the letter says the company “will be required to conduct postmarketing studies” [FDA · Jun 20 · p. 4]; it also says the company “should use modeling and simulation to characterize cytisinicline exposure across reasonably likely range of dialysis scenarios” [FDA · Jun 20 · p. 4].

Not in this record: the text of page 1 of the letter, the FDA's letter of April 22, 2026 and communication of June 4, 2026 that it refers to, the warning letter to the prior manufacturer, and Achieve's filings after Oct 1, 2026. [not in record]